{
    "Clinical Trial ID": "NCT00293384",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Aprepitant, Dexamethasone, Cytoxan & Kytril",
        "  Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.",
        "  Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.",
        "  Days 2 & 3: Aprepitant 80 mg once daily in the morning.",
        "  Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3",
        "  Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes",
        "  Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.",
        "  Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Undergoing autologous peripheral blood stem cell transplantation and stem cell mobilization using cyclophosphamide",
        "  Candidate (per institutional requirements) for autologous peripheral blood stem cell transplantation",
        "  No psychiatric illness or multi-system organ failure",
        "  No nausea at baseline",
        "  PATIENT CHARACTERISTICS:",
        "  SWOG performance status 0-2",
        "  Fewer than 5 alcoholic drinks per day within the past year",
        "  No current illness requiring chronic systemic steroids or requirement for chronic use of anti-emetics",
        "  No gastrointestinal obstruction or active peptic ulcer disease",
        "  AST and ALT  3 times upper limit of normal (ULN)",
        "  Bilirubin  3 times ULN",
        "  Alkaline phosphatase  3 times ULN",
        "  Creatinine  2 mg/dL",
        "  No known hypersensitivity to any component of the study regimen",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective barrier contraception",
        "  No unrelenting hiccups",
        "  PRIOR CONCURRENT THERAPY:",
        "  No chronic therapeutic warfarin > 1 mg dose per day",
        "  No other concurrent investigational agents",
        "  No concurrent oral contraceptives (except for stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine hydrochloride, or diltiazem hydrochloride",
        "  No concurrent illegal drugs"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Proportion of Participants With Controlled Acute Vomiting",
        "  No episodes of vomiting and no rescue medication during first 24 hours after cyclophosphamide administration.",
        "  Time frame: at 0-24 hours",
        "Results 1: ",
        "  Arm/Group Title: Aprepitant, Dexamethasone, Cytoxan & Kytril",
        "  Arm/Group Description: Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.",
        "  Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.",
        "  Days 2 & 3: Aprepitant 80 mg once daily in the morning.",
        "  Aprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3",
        "  Cyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes",
        "  Dexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.",
        "  Granisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: participants  20"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/35 (28.57%)",
        "  Febrile Neutropenia 26/35 (17.14%)",
        "  Diarrhea 1/35 (2.86%)",
        "  Vomiting 22/35 (5.71%)",
        "  Pain * 21/35 (2.86%)",
        "  Infection 22/35 (5.71%)",
        "  Hypokalemia 21/35 (2.86%)",
        "  Hypophosphatemia 21/35 (2.86%)",
        "  Mucositis 21/35 (2.86%)",
        "  Musculokeletal Pain 21/35 (2.86%)",
        "  Hydronephrosis 21/35 (2.86%)"
    ]
}